sergliflozin etabonate

Known as: 2-((4-methoxyphenyl)methyl)phenyl 6-O-ethoxycarbonylglucopyranoside, 2-(4-Methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-beta-D-glucopyranoside 
A benzylphenol glucoside and selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Its prodrug form… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2014
01220092014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine and improve blood glucose… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of sodium-dependent glucose cotransporter 2… (More)
Is this relevant?
2010
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium-dependent glucose cotransporter… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • table III
Is this relevant?
2009
2009
Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves… (More)
Is this relevant?
2009
2009
The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has… (More)
Is this relevant?